Clinical Trial Update: An Imaging Study in Patients With Thyroid Cancer or Head and Neck Cancer With Pertechnetate Made in a Cyclotron (C-PERT) [Phase 2]

View source ↗

Summary

A Phase 2 imaging trial using cyclotron-produced pertechnetate (C-PERT) in patients with thyroid neoplasms or head and neck neoplasms has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Head and Neck Neoplasms
• Thyroid Neoplasms

Drugs mentioned

• C-PERT (cyclotron-produced pertechnetate) (pertechnetate)

Snippet

Sponsor: AHS Cancer Control Alberta | Conditions: Thyroid Neoplasms, Head and Neck Neoplasms | Phase 2 | Status: WITHDRAWN